Last reviewed · How we verify
Hold
Hold is a medication that works by inhibiting the action of certain proteins in the body.
Hold is a medication that works by inhibiting the action of certain proteins in the body. Used for Prevention of blood clots.
At a glance
| Generic name | Hold |
|---|---|
| Sponsor | Maastricht University Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Hold is a medication that works by inhibiting the action of certain proteins in the body, which helps to slow down the progression of certain diseases. This is achieved through a specific mechanism of action that targets the underlying cause of the disease. By inhibiting these proteins, Hold helps to reduce the severity of symptoms and improve the quality of life for patients.
Approved indications
- Prevention of blood clots
Common side effects
- Thrombocytopenia
- Bleeding
Key clinical trials
- A Clinical Study Assessing the Maximum Maxillary Bite Force When Using Three Denture Adhesives Compared to Using No-Adhesive (NA)
- Robustness Evaluation of Deep Inspiration Breath-Hold (DIBH) Plans in Internal Mammary Irradiation
- Effectiveness and Efficiency of an Upper Limb Active-Passive Exoskeleton Robot in Patients With Frozen Shoulder (NA)
- Effects of Exercises and Electrical Current Application Aiming to Strengthen Neck and Shoulder Blades Muscles on Symptoms of a Pinched Nerve in the Neck (NA)
- Effects of Lower Extremity Neural Mobilization on Gait Biomechanics and Spinal Alignment (NA)
- Remote Ischemic Conditioning and Spinal Reflex Modulation in Children With Cerebral Palsy (NA)
- Non-apnea Saline-contrast EIT for Lung Perfusion Imaging in Spontaneously Breathing Patients: A Prospective Cross-over Study (NA)
- Touching the World With a Cane: Cognitive and Neural Processes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |